Mapping Neural Circuit Biotypes to Symptoms and Behavioral Dimensions of Depression and Anxiety.

Anxiety Biotype Clinical translation Depression Functional brain circuit imaging Precision mental health

Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
15 03 2022
Historique:
received: 30 10 2020
revised: 25 06 2021
accepted: 28 06 2021
pubmed: 7 9 2021
medline: 20 4 2022
entrez: 6 9 2021
Statut: ppublish

Résumé

Despite tremendous advances in characterizing human neural circuits that govern emotional and cognitive functions impaired in depression and anxiety, we lack a circuit-based taxonomy for depression and anxiety that captures transdiagnostic heterogeneity and informs clinical decision making. We developed and tested a novel system for quantifying 6 brain circuits reproducibly and at the individual patient level. We implemented standardized circuit definitions relative to a healthy reference sample and algorithms to generate circuit clinical scores for the overall circuit and its constituent regions. In new data from primary and generalizability samples of depression and anxiety (N = 250), we demonstrated that overall disconnections within task-free salience and default mode circuits map onto symptoms of anxious avoidance, loss of pleasure, threat dysregulation, and negative emotional biases-core characteristics that transcend diagnoses-and poorer daily function. Regional dysfunctions within task-evoked cognitive control and affective circuits may implicate symptoms of cognitive and valence-congruent emotional functions. Circuit dysfunction scores also distinguished response to antidepressant and behavioral intervention treatments in an independent sample (n = 205). Our findings articulate circuit dimensions that relate to transdiagnostic symptoms across mood and anxiety disorders. Our novel system offers a foundation for deploying standardized circuit assessments across research groups, trials, and clinics to advance more precise classifications and treatment targets for psychiatry.

Sections du résumé

BACKGROUND
Despite tremendous advances in characterizing human neural circuits that govern emotional and cognitive functions impaired in depression and anxiety, we lack a circuit-based taxonomy for depression and anxiety that captures transdiagnostic heterogeneity and informs clinical decision making.
METHODS
We developed and tested a novel system for quantifying 6 brain circuits reproducibly and at the individual patient level. We implemented standardized circuit definitions relative to a healthy reference sample and algorithms to generate circuit clinical scores for the overall circuit and its constituent regions.
RESULTS
In new data from primary and generalizability samples of depression and anxiety (N = 250), we demonstrated that overall disconnections within task-free salience and default mode circuits map onto symptoms of anxious avoidance, loss of pleasure, threat dysregulation, and negative emotional biases-core characteristics that transcend diagnoses-and poorer daily function. Regional dysfunctions within task-evoked cognitive control and affective circuits may implicate symptoms of cognitive and valence-congruent emotional functions. Circuit dysfunction scores also distinguished response to antidepressant and behavioral intervention treatments in an independent sample (n = 205).
CONCLUSIONS
Our findings articulate circuit dimensions that relate to transdiagnostic symptoms across mood and anxiety disorders. Our novel system offers a foundation for deploying standardized circuit assessments across research groups, trials, and clinics to advance more precise classifications and treatment targets for psychiatry.

Identifiants

pubmed: 34482948
pii: S0006-3223(21)01437-2
doi: 10.1016/j.biopsych.2021.06.024
pmc: PMC9511971
mid: NIHMS1738043
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-571

Subventions

Organisme : NIMH NIH HHS
ID : T32 MH019938
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109985
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA042012
Pays : United States
Organisme : NIMH NIH HHS
ID : F32 MH108299
Pays : United States
Organisme : NHLBI NIH HHS
ID : UH2 HL132368
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH113708
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH101496
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Références

J Neuropsychiatry Clin Neurosci. 2015 Summer;27(3):237-9
pubmed: 26067435
Nat Rev Neurosci. 2013 May;14(5):365-76
pubmed: 23571845
Behav Res Ther. 2018 Feb;101:58-70
pubmed: 29074231
Stat Appl Genet Mol Biol. 2010;9:Article39
pubmed: 21044043
Biol Psychiatry. 2006 Aug 15;60(4):383-7
pubmed: 16780813
JAMA Psychiatry. 2015 Jun;72(6):603-11
pubmed: 25785575
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9078-9083
pubmed: 30979801
Transl Psychiatry. 2018 Mar 6;8(1):57
pubmed: 29507282
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800
Neuroimage Clin. 2021;30:102570
pubmed: 33540370
JAMA. 2017 Apr 18;317(15):1517
pubmed: 28418490
Acta Psychiatr Scand. 2000 Apr;101(4):323-9
pubmed: 10782554
JAMA Psychiatry. 2013 Apr;70(4):373-82
pubmed: 23389382
Neuroimage. 2020 Feb 1;206:116287
pubmed: 31655111
Mol Psychiatry. 2020 Jul;25(7):1537-1549
pubmed: 31695168
J Clin Exp Neuropsychol. 2009 Apr;31(3):278-91
pubmed: 18720178
Lancet Psychiatry. 2016 May;3(5):472-80
pubmed: 27150382
BMC Psychiatry. 2021 Jan 13;21(1):35
pubmed: 33435926
Focus (Am Psychiatr Publ). 2018 Apr;16(2):124-134
pubmed: 31975907
Trials. 2011 Jan 05;12:4
pubmed: 21208417
Depress Anxiety. 2017 Jan;34(1):9-24
pubmed: 27653321
J Pers Assess. 1985 Feb;49(1):71-5
pubmed: 16367493
Mol Psychiatry. 2018 Dec;23(12):2314-2323
pubmed: 30104727
J Clin Exp Neuropsychol. 2009 Apr;31(3):257-77
pubmed: 18720177
Neuropsychopharmacology. 2015 Sep;40(10):2398-408
pubmed: 25824424
Trials. 2013 Jul 18;14:224
pubmed: 23866851
Transl Psychiatry. 2017 Oct 17;7(10):e1248
pubmed: 29039851
Biol Psychiatry. 2012 Apr 1;71(7):611-7
pubmed: 22177602
Nat Methods. 2011 Jun 26;8(8):665-70
pubmed: 21706013
Hum Brain Mapp. 2014 Aug;35(8):3893-902
pubmed: 24453120

Auteurs

Andrea N Goldstein-Piekarski (AN)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

Tali M Ball (TM)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.

Zoe Samara (Z)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.

Brooke R Staveland (BR)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.

Arielle S Keller (AS)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Department of Graduate Program in Neurosciences, Stanford University, Stanford, California.

Scott L Fleming (SL)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Department of Biomedical Informatics, Stanford University, Stanford, California.

Katherine A Grisanzio (KA)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.

Bailey Holt-Gosselin (B)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.

Patrick Stetz (P)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.

Jun Ma (J)

Department of Medicine, University of Illinois at Chicago, Chicago, Illinois; Institute for Health Research and Policy, University of Illinois at Chicago, Chicago, Illinois.

Leanne M Williams (LM)

Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California; Sierra-Pacific Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, California. Electronic address: leawilliams@stanford.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH